Recent Updates
Recently added Catalysts
ANGO Positive Sentiment

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

Monday, September 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AngioDynamics, Inc. has announced that it will report its financial results for the first quarter of fiscal year 2027 on October 8, 2026. The report will be released before the market opens, followed by a conference call at 8:00 am ET to discuss the results. This event highlights the company's ongoing commitment to transparency and communication with stakeholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • AngioDynamics is focused on improving patient quality of life.
  • The company is expanding cancer treatment options.
  • The upcoming financial results may indicate positive growth.

Full Press Release Details

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results. To pa

Frequently Asked Questions

When will AngioDynamics report its Q1 results?

AngioDynamics will report its Q1 results on October 8, 2026.

What time is the conference call for Q1 results?

The conference call will be held at 8:00 am ET on October 8, 2026.

What fiscal year are the results for?

The results are for the first quarter of fiscal year 2027.

What is AngioDynamics focused on?

AngioDynamics focuses on restoring healthy blood flow and expanding cancer treatment options.

ShareAdd on Google
Tags: ANGO AngioDynamics fiscal 2027 financial results conference call NASDAQ: ANGO
Last updated: Sep 28, 2026

Biotech snapshot

Cash runway
$54M liquidity · $0M/mo burn
Low dilution risk
Lead asset
RF ablationPhase 2
Non Small Cell Lung Cancer →